Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...

Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...

Genmab AS (GMAB) reports a 31% revenue increase and outlines strategic plans for 2025 amidst competitive market challenges.

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...